Related Experiment Video
Updated: May 12, 2026
08:34
Robot-assisted Partial Splenectomy
Published on: January 2, 2026
Robot-assisted partial nephrectomy for hilar tumors: perioperative outcomes
Rémi Eyraud1, Jean-Alexandre Long, Devon Snow-Lisy
1Section of Laparoscopic and Robotic Surgery, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Urology
|April 23, 2013
Summary
Robot-assisted partial nephrectomy (RAPN) for kidney tumors near the hilum is safe and effective. Hilar tumor location does not increase risks of transfusion, major complications, or reduced kidney function post-surgery.
Area of Science:
- Urology
- Oncology
- Surgical Innovation
Background:
- Robot-assisted partial nephrectomy (RAPN) is increasingly used for kidney tumors.
- Tumor location, particularly near the renal hilum, can present surgical challenges.
- Evaluating outcomes for hilar versus nonhilar tumors is crucial for surgical planning.
Purpose of the Study:
- To compare perioperative outcomes between robot-assisted partial nephrectomy (RAPN) for hilar and nonhilar kidney tumors.
- To identify predictors of key perioperative outcomes including warm ischemia time (WIT), estimated blood loss (EBL), complications, and renal function.
Main Methods:
- Retrospective review of 364 patients undergoing RAPN.
- Comparison of demographic data and perioperative outcomes between hilar (n=70) and nonhilar (n=294) tumor groups.
- Multivariate analysis to assess predictors of WIT, EBL, complications, and postoperative renal function.
Main Results:
- Hilar tumors were larger and had higher RENAL scores compared to nonhilar tumors.
- Surgeries for hilar tumors were associated with longer operative times, increased WIT, and greater EBL.
- No significant differences were observed in transfusion rates, length of stay, complications, positive margins, or postoperative renal function between the groups.
Conclusions:
- RAPN is a safe and effective procedure for managing kidney tumors located at the hilum.
- Hilar tumor location in RAPN at a high-volume center is not associated with increased transfusion, major complication, or early renal function decline risks.
